Constellation Pharmaceuticals Appoints Patrick Trojer, Ph.D., as Chief Scientific Officer
29 Novembre 2018 - 3:22PM
Constellation Pharmaceuticals, Inc. (the “Company”) (Nasdaq: CNST),
a clinical-stage biopharmaceutical company using its expertise in
epigenetics to discover and develop novel therapeutics, today
announced that Patrick Trojer has been appointed Chief Scientific
Officer, effective immediately.
Dr. Trojer joined Constellation Pharmaceuticals, Inc. (the
“Company” or “Constellation”) as a founding scientist in 2008,
working closely with the initial investors—The Column Group, Third
Rock Ventures, and Venrock—to launch the Company. He has held
positions of increasing responsibility at Constellation, initially
leading biology, then research and, most recently, as senior vice
president, EZH2 franchise and head of translational sciences.
During his tenure at Constellation, he has built a strong
scientific team to generate innovative cancer therapeutics by
targeting various gene regulatory (epigenetic) mechanisms. He
made a significant contribution to building Constellation’s
portfolio of two clinical and multiple preclinical product
candidates. With over 20 years of experience in epigenetics
and transcription and a distinguished publication record, Dr.
Trojer has become a cancer epigenetics thought leader. Dr.
Trojer received a Ph.D. in protein biochemistry and molecular
biology from the Leopold Franzens University in Innsbruck,
Austria. He completed his postdoctoral studies at NYU Medical
School in the laboratory of Dr. Danny Reinberg, a Constellation
founder.
“I’m delighted to announce Patrick’s appointment as Chief
Scientific Officer,” said Jigar Raythatha, CEO of Constellation.
“His depth of knowledge in epigenetics and his experience in
translational sciences have been invaluable in advancing
Constellation’s product pipeline. We look forward to his
continuing leadership as we work to bring several innovative drug
candidates to cancer patients in need.”
“I am honored to serve as Constellation’s Chief Scientific
Officer,” said Dr. Trojer. “In our ten-year history, we have
grown from a small group of pioneering scientists into one of the
leading drug discovery and development organizations in cancer
epigenetics. I look forward to helping to advance our
pipeline of clinical programs and leading the discovery of novel
drug candidates from our cancer epigenetics platform.”
About Constellation Pharmaceuticals, Inc.
Constellation Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company developing novel therapeutics that
selectively modulate gene expression to address serious unmet
medical needs in patients with cancer. The Company has a deep
understanding of how epigenetic and chromatin modifications in
cancer cells and in the tumor and immune microenvironment play a
fundamental role in driving disease progression and drug
resistance. Constellation is driving development of the EZH2
inhibitors CPI-1205 and CPI-0209 for the treatment of metastatic
castration-resistant prostate cancer and other cancers as well as
the BET inhibitor CPI-0610 for the treatment of
myelofibrosis. The Company is also applying its broad
research and development capabilities to explore other novel
targets that directly and indirectly impact gene expression to fuel
a sustainable pipeline of innovative small-molecule product
candidates.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of 1995
that involve substantial risks and uncertainties, including
statements regarding the development status and potential benefit
of the Company’s product candidates. All statements, other
than statements of historical facts, contained in this press
release, including statements regarding the Company’s strategy,
future operations, future financial position, prospects, plans and
objectives of management, are forward-looking statements. Any
forward-looking statements are based on management’s current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in, or implied by,
such forward-looking statements. For a discussion of risks and
uncertainties, any of which could cause the Company’s actual
results to differ from those contained in the forward-looking
statements, see the “Risk Factors” section, as well as discussions
of potential risks, uncertainties, and other important factors, in
the Company’s most recent filings with the Securities and Exchange
Commission.
Contact
Ronald Aldridge Investor RelationsConstellation
Pharmaceuticals+1
617-714-0539ron.aldridge@constellationpharma.com
Lauren ArnoldMedia RelationsMacDougall Biomedical
Communications+1 781-235-3060larnold@macbiocom.com
Constellation Pharmaceut... (NASDAQ:CNST)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Constellation Pharmaceut... (NASDAQ:CNST)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024